Company: CWAN
Filing Date: 2025-03-06
Form Type: S-4/A
Source: 0001193125-25-048570
Chunk: 220

Company: Clearwater Analytics Holdings, Inc.
Filing Date: 2025-03-06
Form: S-4/A
Chunk 220
---
ii) making any disclosure to Enfusion Stockholders if, the Enfusion Board or any committee thereof determines in good faith, after consultation with outside legal counsel, the failure to do so would be inconsistent with its fiduciary duties under applicable law or any disclosure requirements under applicable law, or (iii) making any disclosure that constitutes a “stop, look and listen” communication or similar communication of the type contemplated by Section 14d-9(f) promulgated under the Exchange Act, in each case, so long as any such disclosure does not include any statement that constitutes an Adverse Recommendation Change. Financing Cooperation Each of Clearwater and Clearwater Analytics, LLC (“ Clearwater LLC”) will use its reasonable best efforts to, and will cause each of its subsidiaries and representatives to use reasonable best efforts to, take, or cause to be taken, all actions and do, or cause to be done, all things necessary, proper or advisable to arrange, obtain and consummate the Debt Financing on the terms and subject to the conditions described in the debt commitment letter, dated as of the date of the Merger Agreement (together with all exhibits, annexes, schedules and term sheets attached thereto, the “ Debt Commitment Letter”) and/or the fee letter referred to in the Debt Commitment Letter, including using reasonable best efforts to maintain in full force and effect the Debt Commitment Letter until the Closing, satisfy all applicable conditions to funding of the Debt Financing that are within its or their control, negotiate and enter into definitive agreements with respect to the Debt Financing and consummate the Debt Financing at or prior to the Closing. Without Enfusion’s prior written consent, Clearwater and Clearwater LLC will not permit or agree to any termination of or amendment to, or grant a waiver of any provision under, the Debt Commitment Letter if such amendment or waiver will or would be reasonably expected to, as applicable, have certain negative impacts on the certainty of the Closing as specified in the Merger Agreement, including reducing the aggregate amount of the Debt Financing below a certain required amount and imposing new conditions or expanding existing conditions to the Debt Financing that would reasonably be expected to materially delay or prevent the Closing. Upon prior written request by Enfusion, Clearwater will keep Enfusion informed on a reasonably current basis and in reasonable detail of the status of the Debt Financing and will promptly notify Enfusion of certain other material events specified in the Merger Agreement, including termination of the Debt Commitment Letter or material defaults or material breach of the terms or conditions set forth therein